시장보고서
상품코드
1193091

보툴리눔 톡신 시장 : 제품별(A형 보툴리눔 톡신, B형 보툴리눔 톡신), 용도별(미용, 치료), 최종 사용자별(병원, 전문의와 피부과 클리닉, 기타) - 세계 기회 분석 및 산업 예측(2021-2031년)

Botulinum Toxin Market By Product (Botulinum Toxin Type A, Botulinum Toxin Type B), By Application (Aesthetic, Therapeutic), By End User (Hospitals, Specialty & Dermatology Clinics, Others): Global Opportunity Analysis & Industry Forecast, 2021-2031

발행일: | 리서치사: Allied Market Research | 페이지 정보: 영문 215 Pages | 배송안내 : 2-3일 (영업일 기준)

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

보툴리눔 톡신의 세계 시장은 2021년에 58억 1,490만 달러를 차지하고, 2031년에는 131억 3,272만 달러에 이를 것으로 예측되며, 2022년부터 2031년에 걸쳐 CAGR은 8.6%로 성장하고 있습니다.

보툴리눔 톡신은 알려진 가장 유독한 생물학적 물질 중 하나이며 클로스트리듐 보툴리눔 박테리아에 의해 생산되는 신경독입니다. 보툴리눔균은 항원적으로 구별할 수 있는 8종류의 외독소(A, B, C1, C2, D, E, F, G)를 정제하고 있습니다. 모든 혈청형은 신경근 접합부에서 주요 신경전달물질인 아세틸콜린의 방출을 억제함으로써 신경전달을 방해하고 근마비를 유발한다. A형 보툴리눔 톡신의 주사에 의해 유발되는 근력 저하는 일반적으로 약 3개월 동안 지속됩니다.

보툴리눔 톡신은 현재 다양한 병리학, 특히 사시 및 국소 근긴장 근육 및 의학적 치료에만 부분적으로 반응하는 몇 가지 만성 질환의 관리에 중요한 역할을 한다. 새로운 적응증의 가능성은 급속히 확대되고 있습니다. 미용 분야에서는 얼굴, 턱, 목, 가슴 등 전신 주름과 작은 주름의 수정에서 다한증 등 피부과 분야에 응용이 있습니다. 보툴리눔 톡신의 주사는 일반적으로 내약성이 높으며 부작용은 거의 없습니다. 보툴리눔 톡신을 임상에서 올바르게 사용하기 위해서는 모방근의 기능 해부학에 대한 정확한 지식과 이해가 필요합니다.

보툴리눔 톡신 시장은 미용 목적의 비침습적 외과적 치료 수요 급증, 신제품 출시, 저렴한 가격 증가, 보툴리눔 주사를 포함한 상환 정책 개정으로 예측 기간 동안 큰 성장을 이룬다 예상됩니다. 또한, 보툴리눔 톡신 치료의 수의 증가는 시장의 성장을 더욱 촉진합니다. 그러나 보톡스 시술과 관련된 부작용과 시술비용이 높아지면 신흥지역 시장 성장을 방해할 것으로 예상됩니다. 반면 보툴리눔 톡신의 치료적 사용을 탐구하기 위한 주요 제조업체들이 연구개발 활동에 대한 투자 증가는 보툴리눔 톡신 시장에 큰 성장 기회를 제공할 것으로 예상됩니다.

보툴리눔 톡신 시장은 제품, 애플리케이션, 최종 사용자, 지역별로 구분됩니다. 제품별로는 A형 보툴리눔 톡신과 B형 보툴리눔 톡신으로 분류되며 용도별로는 미용과 치료로 분류됩니다. 최종 사용자를 기반으로 시장은 병원, 전문 및 피부과 클리닉 등으로 분류됩니다.

목차

제1장 소개

제2장 주요 요약

제3장 시장 개요

  • 시장의 정의와 범위
  • 주요 조사 결과
    • 주요 투자 포켓
  • Porter's Five Forces 분석
  • 주요 기업의 포지셔닝
  • 시장 역학
    • 촉진 요인
    • 억제 요인
    • 기회
  • COVID-19 영향 분석

제4장 보툴리눔 톡신 시장 : 제품별

  • 개요
    • 시장 규모 및 예측
  • A형 보툴리눔 톡신
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모·예측 : 지역별
    • 시장 점유율 분석 : 국가별
  • B형 보툴리눔 톡신
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모·예측 : 지역별
    • 시장 점유율 분석 : 국가별

제5장 보툴리눔 톡신 시장 : 응용 분야별

  • 개요
    • 시장 규모 및 예측
  • 에스테틱
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모·예측 : 지역별
    • 시장 점유율 분석 : 국가별
  • 치료용
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모·예측 : 지역별
    • 시장 점유율 분석 : 국가별

제6장 보툴리눔 톡신 시장 : 최종 사용자별

  • 개요
    • 시장 규모·예측
  • 병원
    • 주요 시장 동향, 성장 요인과 기회
    • 시장 규모·예측 : 지역별
    • 시장 점유율 분석 : 국가별
  • 전문 의원·피부과 클리닉
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모·예측 : 지역별
    • 시장 점유율 분석 : 국가별
  • 기타
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모·예측 : 지역별
    • 시장 점유율 분석 : 국가별

제7장 보툴리눔 톡신 시장 : 지역별

  • 개요
    • 시장 규모·예측
  • 북미
    • 주요 동향과 기회
    • 북미 시장 규모·예측 : 제품별
    • 북미 시장 규모·예측 : 용도별
    • 북미 시장 규모·예측 : 최종 사용자별
    • 북미 시장 규모·예측 : 국가별
      • 미국
      • 캐나다
      • 멕시코
  • 유럽
    • 주요 동향과 기회
    • 유럽 시장 규모·예측 : 제품별
    • 유럽 시장 규모·예측 : 용도별
    • 유럽 시장 규모·예측 : 최종 사용자별
    • 유럽 시장 규모·예측 : 국가별
      • 독일
      • 프랑스
      • 영국
      • 이탈리아
      • 스페인
      • 기타 유럽 지역
  • 아시아태평양
    • 주요 동향과 기회
    • 아시아태평양의 시장 규모·예측 : 제품별
    • 아시아태평양의 시장 규모·예측 : 용도별
    • 아시아태평양의 시장 규모·예측 : 최종 사용자별
    • 아시아태평양의 시장 규모·예측 : 국가별
      • 일본
      • 중국
      • 호주
      • 인도
      • 한국
      • 기타 아시아태평양
  • LAMEA
    • 주요 동향과 기회
    • LAMEA의 시장 규모·예측 : 제품별
    • LAMEA의 시장 규모·예측 : 용도별
    • LAMEA의 시장 규모·예측 : 엔드유저별
    • LAMEA의 시장 규모·예측 : 국가별
      • 브라질
      • 사우디아라비아
      • 남아프리카 공화국
      • 기타 LAMEA 지역

제8장 기업 정세

  • 소개
  • 주요 성공 전략
  • 주요 10개사의 제품 매핑
  • 경쟁 대시보드
  • 경합의 히트 맵
  • 주요 발전

제9장 기업 프로필

  • REVANCE THERAPEUTICS INC
  • Medy-Tox, Inc.
  • galderma
  • US WORLDMED, LLC
  • Abbvie Inc(Allergan)
  • DAEWOONG PHARMACEUTICAL
  • Ipsen Group
  • MERZ PHARMA GMBH AND CO. KGAA
  • HUGEL, INC.
  • EVOLUS INC.
ksm 23.03.27

The global Botulinum toxin market accounted for $5814.9 million in 2021, and is expected to reach $13132.72 million by 2031, registering a CAGR of 8.6% from 2022 to 2031.

Botulinum toxin, one of the most poisonous biological substances known, and is a neurotoxin produced by the bacterium Clostridium botulinum. C. Botulinum elaborates eight antigenically distinguishable exotoxins (A, B, C1, C2, D, E, F and G). All serotypes interfere with neural transmission by blocking the release of acetylcholine, the principal neurotransmitter at the neuromuscular junction, causing muscle paralysis. The weakness induced by injection with botulinum toxin A usually lasts about three months.

Botulinum toxins now play a significant role in the management of a wide variety of medical conditions, especially strabismus and focal dystonia and some chronic conditions that respond only partially to medical treatment. The list of possible new indications is rapidly expanding. The aesthetic applications include correction of lines, creases and wrinkling all over the face, chin, neck, and chest to dermatological applications such as hyperhidrosis. Injections with botulinum toxin are generally well tolerated and side effects are few. A precise knowledge and understanding of the functional anatomy of the mimetic muscles is necessary to correctly use botulinum toxins in clinical practice.

The botulinum toxin market is expected to experience significant growth during the forecast period owing to surge in demand for cosmetic non-invasive surgical procedures, new product launches, increase in affordability and amendments in reimbursement policies to cover botulinum injections. In addition, rise in number of botulinum toxin procedure further facilitates the growth of the market. However, side effects associated with Botox procedures and high cost of these procedures are expected to impede the market growth in emerging region. In contrast, rise in investment in R&D activities by major manufacturers to explore the therapeutic use of botulinum toxin are anticipated to provide significant growth opportunities for the botulinum toxin market.

The Botulinum toxin market is segmented on the basis of product, application, end user and region. On the basis of product, the market is classified into botulinum toxin type A and botulinum toxin type B. On the basis of application, the market is divided into aesthetic and therapeutic. On the basis of end user, the market is classified into hospitals, specialty & dermatology clinics and others.

Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

The report provides a comprehensive analysis of the key players that operate in the global botulinum toxin market. The key companies profiled in the report include Merz Pharma GmbH And Co. Kgaa, Abbvie Inc (Allergan), Ipsen Group, Revance Therapeutics Inc, Medy-Tox, Inc., Hugel, Inc., Galderma, Us Worldmed, Llc ,Evolus Inc., and Daewoong Pharmaceutical.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the botulinum toxin market analysis from 2021 to 2031 to identify the prevailing botulinum toxin market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the botulinum toxin market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global botulinum toxin market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Application

  • Aesthetic
  • Therapeutic

By Product

  • Botulinum Toxin Type A
  • Botulinum Toxin Type B

By End User

  • Hospitals
  • Specialty and Dermatology Clinics
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
  • Key Market Players
    • REVANCE THERAPEUTICS INC
    • Medy-Tox, Inc.
    • GALDERMA
    • US WORLDMED, LLC
    • Abbvie Inc (Allergan)
    • DAEWOONG PHARMACEUTICAL
    • Ipsen Group
    • MERZ PHARMA GMBH AND CO. KGAA
    • HUGEL, INC.
    • EVOLUS INC.

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: BOTULINUM TOXIN MARKET, BY PRODUCT

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 Botulinum Toxin Type A
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market share analysis by country
  • 4.3 Botulinum Toxin Type B
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market share analysis by country

CHAPTER 5: BOTULINUM TOXIN MARKET, BY APPLICATION

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 Aesthetic
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market share analysis by country
  • 5.3 Therapeutic
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market share analysis by country

CHAPTER 6: BOTULINUM TOXIN MARKET, BY END USER

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 Hospitals
    • 6.2.1 Key market trends, growth factors and opportunities
    • 6.2.2 Market size and forecast, by region
    • 6.2.3 Market share analysis by country
  • 6.3 Specialty and Dermatology Clinics
    • 6.3.1 Key market trends, growth factors and opportunities
    • 6.3.2 Market size and forecast, by region
    • 6.3.3 Market share analysis by country
  • 6.4 Others
    • 6.4.1 Key market trends, growth factors and opportunities
    • 6.4.2 Market size and forecast, by region
    • 6.4.3 Market share analysis by country

CHAPTER 7: BOTULINUM TOXIN MARKET, BY REGION

  • 7.1 Overview
    • 7.1.1 Market size and forecast
  • 7.2 North America
    • 7.2.1 Key trends and opportunities
    • 7.2.2 North America Market size and forecast, by Product
    • 7.2.3 North America Market size and forecast, by Application
    • 7.2.4 North America Market size and forecast, by End User
    • 7.2.5 North America Market size and forecast, by country
      • 7.2.5.1 U.S.
      • 7.2.5.1.1 Key market trends, growth factors and opportunities
      • 7.2.5.1.2 Market size and forecast, by Product
      • 7.2.5.1.3 Market size and forecast, by Application
      • 7.2.5.1.4 Market size and forecast, by End User
      • 7.2.5.2 Canada
      • 7.2.5.2.1 Key market trends, growth factors and opportunities
      • 7.2.5.2.2 Market size and forecast, by Product
      • 7.2.5.2.3 Market size and forecast, by Application
      • 7.2.5.2.4 Market size and forecast, by End User
      • 7.2.5.3 Mexico
      • 7.2.5.3.1 Key market trends, growth factors and opportunities
      • 7.2.5.3.2 Market size and forecast, by Product
      • 7.2.5.3.3 Market size and forecast, by Application
      • 7.2.5.3.4 Market size and forecast, by End User
  • 7.3 Europe
    • 7.3.1 Key trends and opportunities
    • 7.3.2 Europe Market size and forecast, by Product
    • 7.3.3 Europe Market size and forecast, by Application
    • 7.3.4 Europe Market size and forecast, by End User
    • 7.3.5 Europe Market size and forecast, by country
      • 7.3.5.1 Germany
      • 7.3.5.1.1 Key market trends, growth factors and opportunities
      • 7.3.5.1.2 Market size and forecast, by Product
      • 7.3.5.1.3 Market size and forecast, by Application
      • 7.3.5.1.4 Market size and forecast, by End User
      • 7.3.5.2 France
      • 7.3.5.2.1 Key market trends, growth factors and opportunities
      • 7.3.5.2.2 Market size and forecast, by Product
      • 7.3.5.2.3 Market size and forecast, by Application
      • 7.3.5.2.4 Market size and forecast, by End User
      • 7.3.5.3 UK
      • 7.3.5.3.1 Key market trends, growth factors and opportunities
      • 7.3.5.3.2 Market size and forecast, by Product
      • 7.3.5.3.3 Market size and forecast, by Application
      • 7.3.5.3.4 Market size and forecast, by End User
      • 7.3.5.4 Italy
      • 7.3.5.4.1 Key market trends, growth factors and opportunities
      • 7.3.5.4.2 Market size and forecast, by Product
      • 7.3.5.4.3 Market size and forecast, by Application
      • 7.3.5.4.4 Market size and forecast, by End User
      • 7.3.5.5 Spain
      • 7.3.5.5.1 Key market trends, growth factors and opportunities
      • 7.3.5.5.2 Market size and forecast, by Product
      • 7.3.5.5.3 Market size and forecast, by Application
      • 7.3.5.5.4 Market size and forecast, by End User
      • 7.3.5.6 Rest of Europe
      • 7.3.5.6.1 Key market trends, growth factors and opportunities
      • 7.3.5.6.2 Market size and forecast, by Product
      • 7.3.5.6.3 Market size and forecast, by Application
      • 7.3.5.6.4 Market size and forecast, by End User
  • 7.4 Asia-Pacific
    • 7.4.1 Key trends and opportunities
    • 7.4.2 Asia-Pacific Market size and forecast, by Product
    • 7.4.3 Asia-Pacific Market size and forecast, by Application
    • 7.4.4 Asia-Pacific Market size and forecast, by End User
    • 7.4.5 Asia-Pacific Market size and forecast, by country
      • 7.4.5.1 Japan
      • 7.4.5.1.1 Key market trends, growth factors and opportunities
      • 7.4.5.1.2 Market size and forecast, by Product
      • 7.4.5.1.3 Market size and forecast, by Application
      • 7.4.5.1.4 Market size and forecast, by End User
      • 7.4.5.2 China
      • 7.4.5.2.1 Key market trends, growth factors and opportunities
      • 7.4.5.2.2 Market size and forecast, by Product
      • 7.4.5.2.3 Market size and forecast, by Application
      • 7.4.5.2.4 Market size and forecast, by End User
      • 7.4.5.3 Australia
      • 7.4.5.3.1 Key market trends, growth factors and opportunities
      • 7.4.5.3.2 Market size and forecast, by Product
      • 7.4.5.3.3 Market size and forecast, by Application
      • 7.4.5.3.4 Market size and forecast, by End User
      • 7.4.5.4 India
      • 7.4.5.4.1 Key market trends, growth factors and opportunities
      • 7.4.5.4.2 Market size and forecast, by Product
      • 7.4.5.4.3 Market size and forecast, by Application
      • 7.4.5.4.4 Market size and forecast, by End User
      • 7.4.5.5 South Korea
      • 7.4.5.5.1 Key market trends, growth factors and opportunities
      • 7.4.5.5.2 Market size and forecast, by Product
      • 7.4.5.5.3 Market size and forecast, by Application
      • 7.4.5.5.4 Market size and forecast, by End User
      • 7.4.5.6 Rest of Asia-Pacific
      • 7.4.5.6.1 Key market trends, growth factors and opportunities
      • 7.4.5.6.2 Market size and forecast, by Product
      • 7.4.5.6.3 Market size and forecast, by Application
      • 7.4.5.6.4 Market size and forecast, by End User
  • 7.5 LAMEA
    • 7.5.1 Key trends and opportunities
    • 7.5.2 LAMEA Market size and forecast, by Product
    • 7.5.3 LAMEA Market size and forecast, by Application
    • 7.5.4 LAMEA Market size and forecast, by End User
    • 7.5.5 LAMEA Market size and forecast, by country
      • 7.5.5.1 Brazil
      • 7.5.5.1.1 Key market trends, growth factors and opportunities
      • 7.5.5.1.2 Market size and forecast, by Product
      • 7.5.5.1.3 Market size and forecast, by Application
      • 7.5.5.1.4 Market size and forecast, by End User
      • 7.5.5.2 Saudi Arabia
      • 7.5.5.2.1 Key market trends, growth factors and opportunities
      • 7.5.5.2.2 Market size and forecast, by Product
      • 7.5.5.2.3 Market size and forecast, by Application
      • 7.5.5.2.4 Market size and forecast, by End User
      • 7.5.5.3 South Africa
      • 7.5.5.3.1 Key market trends, growth factors and opportunities
      • 7.5.5.3.2 Market size and forecast, by Product
      • 7.5.5.3.3 Market size and forecast, by Application
      • 7.5.5.3.4 Market size and forecast, by End User
      • 7.5.5.4 Rest of LAMEA
      • 7.5.5.4.1 Key market trends, growth factors and opportunities
      • 7.5.5.4.2 Market size and forecast, by Product
      • 7.5.5.4.3 Market size and forecast, by Application
      • 7.5.5.4.4 Market size and forecast, by End User

CHAPTER 8: COMPANY LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Key developments

CHAPTER 9: COMPANY PROFILES

  • 9.1 REVANCE THERAPEUTICS INC
    • 9.1.1 Company overview
    • 9.1.2 Company snapshot
    • 9.1.3 Operating business segments
    • 9.1.4 Product portfolio
    • 9.1.5 Business performance
    • 9.1.6 Key strategic moves and developments
  • 9.2 Medy-Tox, Inc.
    • 9.2.1 Company overview
    • 9.2.2 Company snapshot
    • 9.2.3 Operating business segments
    • 9.2.4 Product portfolio
    • 9.2.5 Business performance
    • 9.2.6 Key strategic moves and developments
  • 9.3 galderma
    • 9.3.1 Company overview
    • 9.3.2 Company snapshot
    • 9.3.3 Operating business segments
    • 9.3.4 Product portfolio
    • 9.3.5 Business performance
    • 9.3.6 Key strategic moves and developments
  • 9.4 US WORLDMED, LLC
    • 9.4.1 Company overview
    • 9.4.2 Company snapshot
    • 9.4.3 Operating business segments
    • 9.4.4 Product portfolio
    • 9.4.5 Business performance
    • 9.4.6 Key strategic moves and developments
  • 9.5 Abbvie Inc (Allergan)
    • 9.5.1 Company overview
    • 9.5.2 Company snapshot
    • 9.5.3 Operating business segments
    • 9.5.4 Product portfolio
    • 9.5.5 Business performance
    • 9.5.6 Key strategic moves and developments
  • 9.6 DAEWOONG PHARMACEUTICAL
    • 9.6.1 Company overview
    • 9.6.2 Company snapshot
    • 9.6.3 Operating business segments
    • 9.6.4 Product portfolio
    • 9.6.5 Business performance
    • 9.6.6 Key strategic moves and developments
  • 9.7 Ipsen Group
    • 9.7.1 Company overview
    • 9.7.2 Company snapshot
    • 9.7.3 Operating business segments
    • 9.7.4 Product portfolio
    • 9.7.5 Business performance
    • 9.7.6 Key strategic moves and developments
  • 9.8 MERZ PHARMA GMBH AND CO. KGAA
    • 9.8.1 Company overview
    • 9.8.2 Company snapshot
    • 9.8.3 Operating business segments
    • 9.8.4 Product portfolio
    • 9.8.5 Business performance
    • 9.8.6 Key strategic moves and developments
  • 9.9 HUGEL, INC.
    • 9.9.1 Company overview
    • 9.9.2 Company snapshot
    • 9.9.3 Operating business segments
    • 9.9.4 Product portfolio
    • 9.9.5 Business performance
    • 9.9.6 Key strategic moves and developments
  • 9.10 EVOLUS INC.
    • 9.10.1 Company overview
    • 9.10.2 Company snapshot
    • 9.10.3 Operating business segments
    • 9.10.4 Product portfolio
    • 9.10.5 Business performance
    • 9.10.6 Key strategic moves and developments
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제